Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q2 EPS of $4.30, $0.10 better than the analyst estimate of $4.20. Revenue for the quarter came in at $932.9 million versus the...
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q1 EPS of $3.73, $0.11 worse than the analyst estimate of $3.84. Revenue for the quarter came in at $813.7 million versus the...
Jazz Pharmaceuticals (NASDAQ:JAZZ) shares ended the last trading session 9% higher at $146.49. The jump came on an impressive volume with a higher-than-average number of shares...
SPECIAL ALERT: Remember, we need your input to make next week’s new Zacks Ultimate Strategy Session episode the best it can be. There are two ways you can participate:1)...
Jazz Pharmaceuticals (NASDAQ:JAZZ) plc JAZZ announced that the FDA has granted approval to a biologics license application (BLA) seeking approval of its novel asparaginase, Rylaze...
Jazz Pharmaceuticals plc is a biopharmaceutical company. The Company is engaged in developing medicines for people with serious diseases. The Company’s products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, which develops for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy aged seven years of age and older; Xyrem (sodium oxybate) oral solution, which develops for the treatment of both cataplexy and EDS in patients seven years of age and older with narcolepsy; Epidiolex (cannabidiol) oral solution, which develops for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex in patients one year of age or older; Sunosi (solriamfetol); Sativex (nabiximols) oral solution; Zepzelca (lurbinectedin); Rylaze (recombinant Erwinia asparaginase); Vyxeos (daunorubicin and cytarabine) liposome for injection; and Defitelio (defibrotide sodium).
|Average||198.58 (+46.61% Upside)|
|No. of Analysts||19|